Skip to main content
TRANS GENIC GROUP INC. logo

TRANS GENIC GROUP INC. — Investor Relations & Filings

Ticker · 2342 ISIN · JP3635720000 T Professional, scientific and technical activities
Open in API
Filings indexed 68 across all filing types
Latest filing 2024-06-24 M&A Activity
Country JP Japan
Listing T 2342

About TRANS GENIC GROUP INC.

https://transgenic-group.co.jp/

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Recent filings

Filing Released Lang Actions
臨時報告書
M&A Activity Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and is filed with the Fukuoka Local Finance Bureau. The filing reason explicitly states that a resolution regarding a change in a specified subsidiary (特定子会社の異動) was made at the board meeting on June 24, 2024, pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. This type of filing, reporting a significant corporate event like an acquisition or change in control of a subsidiary, is generally classified as a Regulatory Filing (RNS) in this schema, as there is no specific code for 'Change in Subsidiary Status' or 'Acquisition Report' other than the general regulatory category. Given the nature of the disclosure (reporting a specific transaction/event mandated by law) and the lack of a more specific category, RNS is the most appropriate fit. The document is short and contains the core information, not just an announcement of a report.
2024-06-24 Japanese
有価証券報告書－第26期(2023/04/01－2024/03/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which is the standard Japanese equivalent of an Annual Report (10-K). It explicitly states the fiscal year (第26期, 2023-04-01 to 2024-03-31) and is filed with the Fukuoka Local Finance Bureau under the Financial Instruments and Exchange Act. The presence of extensive XBRL-like tagging and financial data confirms it is the full annual report rather than an announcement. FY 2024
2024-06-21 Japanese
確認書
Regulatory Filings
2024-06-21 Japanese
内部統制報告書－第26期(2023/04/01－2024/03/31)
Regulatory Filings
2024-06-21 Japanese
臨時報告書
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled "臨時報告書" (Extraordinary Report/Timely Disclosure Report) and explicitly states in Section 1 that it is being filed pursuant to Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were passed at the Annual General Meeting (AGM) held on June 20, 2024. Section 2 details the resolutions, including dividend approval, articles of incorporation changes, and director/auditor elections, along with the voting results. This structure—reporting the results of a shareholder meeting—is characteristic of a filing announcing the outcome of a general meeting. Since the content is the official results of shareholder votes, the most appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). Although it relates to the AGM, DVA specifically covers the voting results, which is the core content here.
2024-06-21 Japanese
臨時報告書
Regulatory Filings Classification · 100% confidence The document is titled "臨時報告書" (Extraordinary Report) and is filed with the Fukuoka Local Finance Bureau. The filing reason explicitly states that an event significantly impacting the company's financial condition has occurred, citing Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act. The content details a specific financial event: recording an impairment loss on subsidiary shares (関係会社株式評価損). This structure—a formal, non-periodic filing detailing a significant, sudden event impacting financials—is characteristic of a Japanese Extraordinary Report, which generally corresponds to the SEC's 8-K filing. Among the provided codes, 'RNS' (Regulatory Filings) is the most appropriate general category for miscellaneous, non-scheduled regulatory disclosures that don't fit the specific periodic reports (10-K, IR) or specific event types (DIV, M&A, etc.). While it details a financial event, it is not an Earnings Release (ER) or Interim Report (IR), but rather a specific disclosure mandated by law regarding a significant event. Given the options, RNS (Regulatory Filings) serves as the best fit for a Japanese 'Extraordinary Report' (臨時報告書) that is not covered by other specific categories like DEF 14A, 10-K, or ER.
2024-05-10 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.